Why did it drop so much again after hours???

After-hours saw another big drop, it's absolutely ridiculous, does this thing even have a bottom?

Let's try to find the reasons from the earnings call

The biggest risk theme in this earnings call was: GLP‑1/compounded drugs and regulatory scrutiny + the resulting volatility in growth and revenue recognition. Next was: the drag on profit margins from international expansion, and the phased pressure on margins from expense investments (AI/technology/new specialties/brand advertising).

1. Regulatory and Legal Scrutiny: Compounded GLP‑1, and the "Pill" Incident
The retail community directly asked: "Regulatory and legal scrutiny... how to mitigate the risk of a potential ban on compounded GLP‑1?" (Question)
The CEO's core response was that "compounded GLP‑1 patients are a relatively small minority of subscribers," "the company has always had more than one treatment," and "most revenue and profit come from outside weight loss," pointing the hedging path towards: labs, menopause, low testosterone, peptide R&D, international expansion, etc. (CEO)
Analysts pressed for regulatory progress on the "pill launch and subsequent withdrawal," and whether there was communication with the FDA/DOJ:
The CEO said "there may not be much to say," the reason for withdrawal was "prioritizing engagement and relationships with ecosystem stakeholders"; regarding the FDA/DOJ, also stated "can't share too much about ongoing matters." (CEO)
Investment implication: When the market is most worried about "regulation/enforcement/compliance," limited management disclosure amplifies the uncertainty premium.

2. Earnings Volatility Point: "Timing" Pressure on Revenue Recognition (The Key Pain Point in Q1 Guidance)
The CFO provided very specific assumptions in the 2026 outlook:
Q1 faces about $65 million revenue pressure from "shipping cadence changes" in the weight loss business due to the 503A fulfillment transition; and noted similar pressure in 2025 was about $40 million.
Emphasized this "only affects the timing of revenue recognition, not demand or engagement," and stated Q4 weight loss subscriptions were up 70% YoY, demand remains strong. (CFO)
But from a market perspective, "unchanged demand" and "weaker revenue recognition/guidance" can coexist; and the stock price often trades on "reported growth and margins" first.

3. Margin Pressure: Q4 Gross Margin Decline, 2026 EBITDA Margin Guidance on the Low Side
Q4 gross margin declined about 2 pct QoQ to 72%, reasons include: international revenue growth (structurally lower margin/higher cost), new specialty launch expenses, and "shorter shipping cycles" in the weight loss area, etc. (CFO)
Expense side: G&A deleveraged due to increased international staff and executive hiring; Technology & Development cost ratio rose to 7% (engineering and AI talent investment). (CFO)
Management was clear: during the international expansion phase, they are not pursuing significant margin expansion, many markets will operate at or near breakeven, "share first, profit later." (CFO)
Investment implication: This suppresses "short-term margin imagination," especially when valuation is sensitive to margins.

4. International M&A Execution Risk and Capital Allocation Risk
Eucalyptus is the "largest acquisition to date," with a complex consideration structure (approx. $240 million upfront, the rest in escrow/earnouts payable through 2029). (CFO)
The CFO mentioned considering "strengthening the balance sheet, and dilution methods," while emphasizing primary funding from the existing balance sheet and domestic cash flow. (CFO)
Investment implication: The market may worry about follow-on financing/dilution, M&A integration underperformance, and cross-market compliance and operational complexity.

In a nutshell:
The call showed HIMS remains strong in subscription scale, product expansion, and cash flow, but the market cares more about: significantly weaker 2026 (especially Q1) growth and margin guidance + increased uncertainty from GLP‑1/regulation and revenue recognition volatility + international M&A and investment cycles lengthening the time to realize returns; these factors combined explain the post-earnings stock plunge "re-pricing."$Hims & Hers Health(HIMS.US) $Defiance Daily Target 2X Long HIMS ETF(HIMZ.US)